Melanoma | Norton Healthcare

Indication: Melanoma

A Randomized Phase II, Open-label, Active-controlled, Multicenter Study Investigating the Efficacy and Safety of UV1 Vaccination in Combination with Nivolumab and Ipilimumab as First-line Treatment of Patients with Unresectable or Metastatic Melanoma (UV1-202)

Sub-indication: Dermatologic Malignancies

Study Type: Drug Study

Principal Investigator: Jaspreet Grewal, M.D.
Norton Cancer Institute

Sponsor: Sponsor: Ultimovacs

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.